Table 3. Preoperative chemoradiotherapy versus surgery alone.

Author	Treatment	Histology	n	Resection rate (%)	Mortality (%)	MST (months)	Survival rate (%)	OS
Nygaard (1992)	CDDP/BLM/35 Gy + Surgery	SCC	53	55 (R0)	24	NA	23 (2 year)	NS
	Surgery alone		50	37 (R0)	13	NA	13 (2 year)
Apinop (1994)	5-FU/CDDP/40 Gy + Surgery	SCC	35	NA	14	10	26 (3 year)	NS
	Surgery alone		34	NA	15	7	20 (3 year)
Le Prise (1994)	5-FU/CDDP/20 Gy + Surgery	SCC	41	85 (R0)	9	11	19 (3 year)	NS
	Surgery alone		45	84 (R0)	7	11	14 (3 year)
Bosset (1997)	CDDP/37 Gy + Surgery	SCC	143	81 (R0)	12	19	39 (3 year)	NS
	Surgery alone		139	69 (R0)	4	19	37 (3 year)
Urba (2001)	5-FU/CDDP/VBL/45 Gy + Surgery	AC/SCC	50	90 (R0)	2	17	30 (3 year)	NS
	Surgery alone		50	90 (R0)	4	18	16 (3 year)
Lee (2004)	5-FU/CDDP/46 Gy + Surgery	SCC	51	69 (R0)	2	28	55 (2 year)	NS
	Surgery alone		50	84 (R0)	2	27	57 (2 year)
Burmeister (2005)	5-FU/CDDP/35 Gy + Surgery	AC/SCC	128	80 (R0)	5	22	NA	NS
	Surgery alone		128	59 (R0)	5	19	NA
Natsugoe (2006)	5-FU/CDDP/40 Gy + Surgery	SCC	22	NA	5	NA	57 (5year)	NS
	Surgery alone		23	NA	0	NA	41 (5 year)
Tepper (2008)	5-FU/CDDP/50.4 Gy + Surgery	AC/SCC	30	86	0	54	39 (5 year)	p = 0.002
	Surgery alone		26	88	4	22	16 (5 year)
Lv (2010)	PTX/CDDP/41.4 Gy + Surgery	SCC	80	97 (R0)	3.8	53	44 (5 year)	p = 0.005
	Surgery alone		80	80 (R0)	0	36	34 (5 year)
Van Hagen (2012)	5-FU/CDDP/45 Gy + Surgery	AC/SCC	98	94 (R0)	11.1	32	41 (5 year)	NS
	Surgery alone		97	92 (R0)	3.4	41	34 (5 year)
Mariette (2014)	PTX/CBDCA/41.4 Gy + Surgery	AC/SCC	175	92 (R0)	3.4	49	59 (3 year)	p = 0.003
	Surgery alone		188	69 (R0)	3.8	24	44 (3 year)

MST: mean survival time; OS: overall survival; CDDP: cisplatin; BLM: bleomysin; SCC: squamous cell carcinoma; NS: not significant; 5-FU: 5 fluorouracil; NA: not available; VL: vinblastine; AC: adenocarcinoma; PTX: paclitaxel; CBDCA: carboplatin